Novo Nordisk’s (NVO) etavopivat was granted FDA orphan designation for treatment of thalassemias, according to a post on the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- NVO Lawsuit Alert! Class Action Lawsuit Against Novo Nordisk A/S
- Eli Lilly launches weight-loss drug Mounjaro in India, Reuters says
- Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
- Eli Lilly (LLY) Leads India’s Weight-Loss Drug Race with Mounjaro
- Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching Barrier